Lumos Pharma, Inc. (LUMO) Tops Q3 EPS by 85c

Lumos Pharma, Inc. (NASDAQ: LUMO) reported Q3 EPS of $0.21, $0.85 better than the analyst estimate of ($0.64).

“This past quarter was marked by significant achievements leading to the initiation of our Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency patients and the previously announced sale of our PRV in July,” commented Rick Hawkins, Chairman, CEO and President of Lumos Pharma. “We are thrilled to advance our LUM-201 program and look forward to building upon this momentum as we continue our efforts to expand our business and pipeline.”

For earnings history and earnings-related data on Lumos Pharma, Inc. (LUMO) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Algorhythm Holdings (RIME) Tops Q2 EPS by 54c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c